Top Story

PD-L1 expression linked to pembrolizumab activity in advanced NSCLC

PD-L1 expression linked to pembrolizumab activity in advanced NSCLC
April 19, 2015

Read the Perspective from Suzanne L. Topalian, MD

PHILADELPHIA — Pembrolizumab yielded durable response rates and demonstrated tolerability in previously treated and treatment-naive patients with non–small cell lung cancer, according to study results presented at the American Association for Cancer Research Annual Meeting.

Patients with programmed death ligand-1 (PD-L1) expression in at least 50% of their tumor cells were more likely to respond to treatment with pembrolizumab (Keytruda, Merck), results showed.

Meeting News Coverage

SLNB used in patients with thin melanomas prior to guidelines

April 18, 2015
NEW YORK — Sentinel lymph node biopsy was used in patients with thin melanomas who did not have high-risk features and who had a very low risk for sentinel lymph…
Meeting News Coverage

HD IL-2 extends OS in malignant melanoma

April 18, 2015
NEW YORK — Patients with metastatic melanoma treated with high-dose interleukin-2 demonstrated improved OS compared with historical reference standards, according…

Oncology Nursing Society to kick off its 40th Annual Congress

April 17, 2015
The Oncology Nursing Society will kick off its 2015 Annual Congress on Wednesday, April 22 in Orlando, Fla., marking its 40th year of providing comprehensive nursing…
FDA News

FDA grants orphan drug designation to Samcyprone for malignant stage IIb to IV melanoma

April 17, 2015
RXi Pharmaceuticals announced it has received orphan drug designation from the FDA for Samcyprone, its clinical candidate for treating malignant melanoma stage IIb to…
More News Headlines »
CME
Hematology Oncology Case Consults

Diagnosis and Management of Hemophilia

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of the patient with hemophilia supplemented with a case…
More »
Meeting News Coverage Video
VIDEO: Ongoing phase 3 trial evaluates patient-specific vaccine in metastatic melanoma

VIDEO: Ongoing phase 3 trial evaluates patient-specific vaccine in metastatic melanoma

April 12, 2015
Robert O. Dillman, MD, vice president of oncology at NeoStem Inc., provides an overview of a phase 3 trial evaluating…
More »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
morganatic-roan
morganatic-roan